Atom Bioscience
- Biotech or pharma, therapeutic R&D
Atom Therapeutics Co. Ltd. (formerly Atom Bioscience), is a clinical stage biotechnology company founded in 2012, developing best-in-class small molecule drugs for treatment of metabolic, inflammatory and cardiovascular diseases.
Atom’s lead product, ABP-671, a global multicenter Phase 2b/3 clinical trial, including the US, for treatment of chronic gout and hyperuricemia just completed and data readout is expected in Q2/2025.. ABP-671 has shown good efficacy, safety and tolerability in completed clinical trials. It is more potent and significantly less toxic than existing drugs on the market.
Another small molecule, ABP-745 for acute gout, has demonstrated safety and efficacy in completed Phase 1 clinical trials in the US. ABP-745 is in Phase 2 clinical trials for acute gout flare treatment and Phase 2 multicounty clinical trial is planned to start in Q3/2025. Additional indications for ABP-745 include ALS and atherosclerosis.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}